Pulmonary Hypertension

In PAH, RNF213 Gene Variant a Risk Factor for Poor Outcomes, Study Says - Pulmonary Hypertension News In PAH, RNF213 Gene Variant a Risk Factor for Poor Outcomes, Study Says - Pulmonary Hypertension News Posted: 30 Sep 2019 06:00 AM PDT Patients with pulmonary arterial hypertension (PAH) who carry a specific mutation in the RNF213 gene have poor clinical outcomes and worse response to combination treatments, according to a study from Japan. The study, " Poor outcomes in carriers of the RNF213 variant (p.Arg4810Lys) with pulmonary arterial hypertension ," was published in  The Journal of Heart and Lung Transplantation . A 2018 study found that approximately 10% of the patients with idiopathic PAH have a specific variant in the RNF213 gene — rs112735431, or p.Arg4810Lys — consisting of an amino acid substitution of arginine to lysine in the RNF213 protein. This gene alteration has already been a...

Riociguat fails to improve pneumonia-associated pulmonary hypertension: RISE-IIP - Healio Riociguat fails to improve pneumonia-associated pulmonary hypertension: RISE-IIP - Healio In PAH, RNF213 Gene Variant a Risk Factor for Poor Outcomes, Study Says - Pulmonary Hypertension News New drug target discovered for the lung disease PAH: In mice, blocking a key protein prevents dangerous lung artery thickening - Science Daily Riociguat fails to improve pneumonia-associated pulmonary hypertension: RISE-IIP - Healio Posted: 12 Sep 2019 07:11 AM PDT Among patients with idiopathic interstitial pneumonia-associated pulmonary hypertension, treatment with riociguat was linked to an increase in adverse events with no significant evidence of benefit, according to the RISE-IIP trial. In fact, the international, multicenter, double-blind, randomized, placebo-controlled phase 2b trial was terminated early due to a higher incidence o...

Growth Differentiation Factor-15 Linked to Transplant-Free Survival in PH - Pulmonology Advisor Growth Differentiation Factor-15 Linked to Transplant-Free Survival in PH - Pulmonology Advisor Posted: 27 Sep 2019 03:00 AM PDT Growth differentiation factor-15 (GDF-15) could be a promising biomarker to identify low-risk patients with normal GDF-15 levels, potentially serving as a predictor for mortality in adults with pulmonary hypertension (PH), according to study results published in Heart . This single-center, prospective, observational cohort study included adults diagnosed with PH at their tertiary-care center between May 2012 and October 2016 (N=103). Researchers defined diagnostic right heart catheterization as the baseline and defined PH as a mean pulmonary artery pressure ≥25 mm Hg. To assess the biomarker, they sampled venous blood during the diagnostic right heart catheterization for study purposes only. Investigators used an elec...

Pulmonary hypertension is elevated lung blood pressure - News - Sarasota Herald-Tribune Pulmonary hypertension is elevated lung blood pressure - News - Sarasota Herald-Tribune Riociguat fails to improve pneumonia-associated pulmonary hypertension: RISE-IIP - Healio Selexipag Functionally Improves Pulmonary Hypertension Patients with COPD - MD Magazine NORD 2019 Rare Disease Summit Set for Oct. 21-22 in Washington, DC - Pulmonary Hypertension News Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease - MD Linx Pulmonary hypertension is elevated lung blood pressure - News - Sarasota Herald-Tribune Posted: 09 Sep 2019 12:00 AM PDT Dear Dr. Roach: I read an article about a study the Mayo Clinic did using 20 mg tablets of sildenafil for pulmonary arterial hypertension and that it improved walking distance by 75%. Is there an upper age limit for a person using this medication...

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): A randomised, placebo-controlled phase 2b study - MD Linx Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): A randomised, placebo-controlled phase 2b study - MD Linx Posted: 06 Sep 2019 12:00 AM PDT [unable to retrieve full-text content] Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): A randomised, placebo-controlled phase 2b study    MD Linx You are subscribed to email updates from "idiopathic pulmonary hypertension" - Google News . To stop receiving these emails, you may unsubscribe now . Email delivery powered by Google Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States

Common Lung Infections May Trigger PAH in People with At-risk Mutations, Rat Study Finds - Pulmonary Hypertension News Common Lung Infections May Trigger PAH in People with At-risk Mutations, Rat Study Finds - Pulmonary Hypertension News Posted: 30 Aug 2019 12:00 AM PDT Lung inflammation caused by a seemingly treatable and common infection may drive the onset of pulmonary arterial hypertension (PAH) in people who carry genetic risk factors for the disease. A simple viral infection — such as a bad flu — was able to trigger PAH development in rats with a mutation in the Bmpr2 gene, a known genetic risk factor for PAH, Stanford researchers report. "It's a kind of one-two punch [mechanism]. Basically, the first hit is the mutation, and the second hit is inflammation in the arteries of the lungs. You can be healthy and carrying this mutation, and all of the sudden you get a bacterial or viral infectio...